Search

everythinglearnresearchcommunity

for

Search:↓

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

Nanoparticle systems make cancer treatment less toxic.

HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Glibenclamide slows breast cancer cell growth by stopping cell division.

Some breast cancer chemotherapy can cause permanent hair loss.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Core symptoms in breast cancer chemotherapy remain stable, aiding targeted interventions.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Dietary phytoestrogens do not significantly affect testicular cancer risk.

DMBT1 and galectin-3 may help suppress epithelial skin cancer.

Raman spectroscopy could effectively guide skin cancer surgery by identifying tumor margins.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Tryptanthrin effectively suppresses non-melanoma skin cancer and is safe for normal skin.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Reduced sexual drive may be linked to male breast cancer, while anti-estrogenic factors might lower the risk.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Natural products can help overcome cancer drug resistance.

Curcumin may be an effective and safer anticancer agent by regulating key cell pathways.

Permanent hair dye use may increase bladder cancer risk, especially in female smokers with certain genetic traits.